Navigation Links
Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting
Date:4/28/2009

of the side effects," said Paul Pockros, M.D., division head of gastroenterology and hepatology at Scripps Clinic and the principal investigator of the study. "A safe, easily tolerated alternative such as AST-120 would be of great benefit in the management of these patients."

The ASTUTE Trial ("AST-120 Use for the Treatment of Hepatic Encephalopathy") is a Phase 2 multi-site, randomized, double-blind, placebo-controlled 8-week study in up to 150 patients with MHE. Patients will be evaluated on neurocognitive improvement at the end of the study, defined as the change in the global summary score of the RBANS or Repeatable Battery for the Assessment of Neuropsychological Status.

"The ASTUTE trial will use a battery of neuropsychometric tests to assess the efficacy of AST-120 in an MHE population," said Scott Harris, M.D., Ocera's chief medical officer, "Up to 60 percent of patients with cirrhosis have MHE and impaired neurocognitive function, a condition for which no drugs are approved."

About AST-120

AST-120 is a novel microspherical carbon adsorbent with a selective adsorption profile for a variety of unwanted substances in the digestive tract. These substances may be responsible for a number of conditions, including Hepatic Encephalopathy (HE), Irritable Bowel Syndrome (IBS), and pouchitis. They include ammonia, indoles (serotonin, octopamine), histamine, secondary bile acids, advanced glycation endproducts (AGE), and certain bacterial toxins. Ocera licensed the compound from the Kureha Corporation (Japan) in 2005.

About Ocera Therapeutics, Inc.

Ocera Therapeutics, based in San Diego, California, USA, is a privately held biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat acute and chronic liver diseases and a broad range of gastrointestinal disorders. In addition to AST-120, Ocera is developing OCR-002 in he
'/>"/>

SOURCE Ocera Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ocera Therapeutics Announces Positive Results with AST-120 in Pouchitis
2. Ocera Therapeutics Closes $35.5 Million Series C Financing
3. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
4. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
5. Dr Stephan Rietiker Joins BioCeramic Therapeutics
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Understanding the need for better quality and ... gap that currently exists in this area, ChanTest has ... of validated ion channel and GPCR cell lines. ... ion channels control many critical physiological functions throughout the ... potential to treat a variety of human diseases. ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 EvoDerma ’s ... convenience. This rejuvenating device now comes with a second treatment ... over time. , The new cup is thinner on the ... works to target rough, thin and uneven surfaces on the ... cup for a stimulating treatment on areas such as the ...
(Date:7/10/2014)... July 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, ... today announced an agreement with Lineagen, Inc., ... Lineagen,s NextStep Dx PLUS.  Lineagen, focused ... neurological disorders, currently offers FirstStep Dx ... service used by healthcare providers as a ...
(Date:7/10/2014)... microscopic polymer light resonators that expand in the ... Photonics Laboratory have developed new optical sensors with ... sensors are ideal for detecting trace gas concentrations ... nature, and immunity to electromagnetic interference. , Although ... the MIT team conceived an extremely sensitive, compact ...
Breaking Biology Technology:Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Swell new sensors 2
... ... Presence in China, CAMBRIDGE, Mass., April 22 ... a major new research and,development center in Beijing. The initiative is ... a,long-term presence in China., The new facility will be used ...
... to Threat of Bioterrorism, Says UK Board ... Member General Lord Guthrie, ... to develop and deploy technology that can neutralize and destroy,a biohazardous ... has partnered with General Lord Guthrie,former chief of the British Defense ...
... April 22 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc.,(,Lorus,), ... and,development of pharmaceutical products and technologies for ... of a development program aimed at,expanding the ... for the treatment of superficial bladder cancer., ...
Cached Biology Technology:Genzyme to Build New R&D Center in Beijing 2Genzyme to Build New R&D Center in Beijing 3Genzyme to Build New R&D Center in Beijing 4Genzyme to Build New R&D Center in Beijing 5Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection 2Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection 3Lorus initiates development program exploring novel route of administration for LOR-2040 2Lorus initiates development program exploring novel route of administration for LOR-2040 3Lorus initiates development program exploring novel route of administration for LOR-2040 4
(Date:7/10/2014)... of enzymes known as heme enzymes, due to the ... At the centre of the heme cofactor is an ... reacting heme is in an intermediate state called Compound ... is whether this oxidation involves just an oxygen atom ... question has implications for understanding oxidative processes within living ...
(Date:7/10/2014)... (ACS) announced today that Courtney Aldrich, Ph.D., will ... Diseases as editor-in-chief. With the first issue ... journal will meet a growing demand for a ... , "Our vision is to develop a journal ... the basic science that advances the field and ...
(Date:7/10/2014)... from The University of Texas Health Science Center at ... (IYG), a health education program designed to delay sexual ... dating violence behaviors among minority youth. , According to ... of high school youth are victims of physical dating ... percent are victims of emotional dating violence. Previous studies ...
Breaking Biology News(10 mins):Neutron crystallography solves long-standing biological mystery 2Neutron crystallography solves long-standing biological mystery 3ACS Infectious Diseases: Unique chemistry journal names editor 2It's Your Game ... Keep It Real reduces dating violence among minority youth 2
... NEW YORK, February 4, 2011 A defining feature ... today,s age of computational science, this means higher standards ... that generated the results along with the published research ... widely accessible, facilitating re-use and verification of results. ...
... the annual meeting of the American Association for the Advancement ... climate change could increase exposure and risk of human illness ... studies projecting impacts to be felt within 30 years. ... warmest for sea surface temperatures, NOAA and our partners are ...
... Among the many differences between girls and boys, add the ... the list. , Results of a double-blind, placebo-controlled, dose-response study ... general, boys get a greater rush and more energy from ... caffeine had a positive effect on their athletic performance. Girls ...
Cached Biology News:AAAS Symposium: New research facilitates scientific knowledge transfer 2Climate projections show human health impacts possible within 30 years 2Climate projections show human health impacts possible within 30 years 3Climate projections show human health impacts possible within 30 years 4High-caffeine-consuming boys get greater rush from caffeine than girls 2High-caffeine-consuming boys get greater rush from caffeine than girls 3
...
Jak3 Antibody Ship: Hot Store: -20 C...
WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Applications: Western blotting Stability: Room temperature, indefinitely ...
Biology Products: